NASDAQ: REPL · Life Sciences · 5 alerts · CIK 1737953
Share price
$21.41Close, Nov 16
Market cap
$2.03B
Shares outstanding
94.8MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Replimune Group, Inc. filings on SEC EDGAR ↗
Replimune Group Insider Joseph P. Slattery Sells $113K of Stock
Joseph P. Slattery sold 5,200 shares of Replimune Group, Inc. at $21.80 a share, worth $113K in total on Nov 9, 2026. Shares held after the trade: 1,467 (-78.0%).
Replimune Group Insider Kapil Dhingra Sells $408K of Stock
Kapil Dhingra sold 21,500 shares of Replimune Group, Inc. at $19.00 a share, worth $408K in total on Nov 2, 2026. Shares held after the trade: 21,669 (-49.8%).
Replimune Group, Inc. reported a net loss of $126.9 million for the six months ended September 30, 2026, an improvement from the $169.8 million loss in the prior year period. The company significantly strengthened its cash position to $307.8 million through the issuance of common stock and pre-funded warrants, while transitioning to a commercial-stage biotechnology company.
Replimune Group reported financial results for its fiscal second quarter 2027 and provided a commercial update on the U.S. launch of TUDRIQEV for advanced melanoma. The product became commercially available on October 6, 2026, with more than 15 institutions already prescribing the therapy and over 70% of priority accounts engaged for adoption.
Term
fiscal second quarter ended September 30, 2026
“TUDRIQEV is now available to patients in urgent need. The response from physicians has been enthusiastic and both oncologists and interventional radiologists are eager to bring TUDRIQEV into their practices. They value the broad label that lets them treat patients immediately after progression on a PD-1 based therapy. We are focused on reaching as many of these patients as possible.”
Replimune Group held its 2026 Annual Meeting of Stockholders where shareholders approved an amendment to the Certificate of Incorporation to double the number of authorized shares of common stock from 150 million to 300 million. Stockholders also ratified the selection of PricewaterhouseCoopers LLP as the independent auditor and approved executive compensation on an advisory basis.